BioNano Genomics Inc vs Global E Online Ltd — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while Global E Online Ltd trades at $40.26 (market cap $6.87B). The key difference: Global E Online Ltd is far larger — about 502.9× BioNano Genomics Inc's market cap, and Global E Online Ltd is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | GLBE | |
|---|---|---|
Market Cap | $13.66M | $6.87B |
Sector | Health | Technology |
52-Week High | $4.92 | $42.32 |
52-Week Low | $1.06 | $27.54 |
Enterprise Value | $16.26M | $6.34B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
GLBE trades at $39.76, down 3.38% on the day, with a bullish technical signal from moving averages and strong analyst support. The company reported Q2 2026 earnings that beat expectations, with revenue up 39% year-over-year and an adjusted EBITDA margin expansion to 20.9%. Recent news highlights the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorization.
The outlook is positive, with 100% buy ratings from analysts and a consensus price target of $44.75 implying 12.5% upside. Key opportunities include robust revenue growth and margin expansion, while risks involve high valuation multiples and insider selling activity. The stock's trajectory hinges on continued execution of its global e-commerce enablement strategy.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →